Primary outcomes
thyroid pain, pain
SUBACUTE THYROIDITIS
The mean duration of PSL treatment was 34.62 ± 14.12 days in the experimental group and 41.18 ± 16.89 days in the control group, resulting in a difference of −6.56 ± 15.55 days between the two groups. The non-inferiority test showed that the duration of PSL treatment was non-inferior in the experimental group compared with that in the control group (with a noninferiority margin of 7 days, pComparison of the total duration of prednisolone treatment, relief time of pain, and complete resolution time of pain between the Low dose group and the Standard dose group. (A) the total duration of prednisolone treatment (days) for patients with subacute thyroiditis. (B) Differences between groups (Low-dose group – Standard-dose group) and non-inferiority testing for the total duration of prednisolone treatment. (C) the relief time of thyroid pain (h) for patients with subacute thyroiditis. (D) the complete resolution time of thyroid pain (h) for patients with subacute thyroiditis. PSL: prednisolone.The sensitivity analysis showed that the difference in the duration of PSL treatment between the two groups was −6.42 ± 14.35 (34.20 ± 14.17 